Skip to main content
. 2023 Aug 18;7(5):382–388. doi: 10.1177/24741264231191339

Table 2.

Comparison of Endophthalmitis Rates Between GVP and PFS by Medication Type.

Medication Glass Vial Preparation Prefilled Syringes
Infections Total Injections Infection Rate, %
(per No. of Injections)
Infections Total Injections Infection Rate, %
(per No. of Injections)
Relative Risk
(95% CI)
P Value
Ranibizumab combined a 13 34 790 0.037
(1 of 2702)
17 112 809 0.015
(1 in 6666)
0.403
(0.196-0.830)
.017 *
Aflibercept 41 68 076 0.060
(1 of 1666)
7 29 899 0.023
(1 in 4348)
0.389
(0.174-0.866)
.018 *
Total 54 102 866 0.052
(1 of 1923)
24 142 708 0.017
(1 in 5882)
0.320
(0.198-0.518)
<.001 **
a

Includes doses 0.5 mg/0.05 mL and 0.3 mg/0.05 mL.

*

p < .05; **p < .001.